WASHINGTON (Reuters) -Shares of Cassava Sciences fell 10% in post-market trading on Thursday after the U.S. Securities and ...

The U.S. Securities and Exchange Commission said on Thursday that it charged Cassava Sciences and two of the company's former ...

Shares of Cassava Sciences Inc. dropped more than 10% in the extended session Thursday after announcing a settlement with U.S ...

AUSTIN, Texas, Sept. 26, 2024 (GLOBE NEWSWIRE) -- (“Cassava” or the “Company”) (Nasdaq: SAVA), a biotechnology company ...

Cassava and former executives were charged Thursday by the SEC with making misleading claims in 2020 about trials for the ...

Drugmaker Cassava Sciences Inc. and two former executives agreed to pay more than $40 million to resolve US Securities and ...

The Securities and Exchange Commission alleged that a researcher for the company manipulated trial data to make its drug ...

Cassava Sciences and two former executives will pay more than $40 million to settle charges related to misleading statements made about a clinical trial for the company's purported therapeutic ...

Cassava Sciences' stock rose 9% after completing a trial of its Alzheimer's drug, Simufilam, but the company's future remains ...

Following our analysis of the options activities associated with Cassava Sciences, we pivot to a closer look at the company's ...

Discover how Cassava Sciences Inc. secures a patent for innovative pharmaceutical compositions using crystalline and amorphous polymorphs, enhancing therapeutic efficacy.

Cassava's financial challenges and data integrity concerns remain critical. Learn why SAVA stock is rated a strong sell given ...